Abstract
Recent decades, there is significant progress in understanding the mechanisms of tumor progression and immune evasion. The newly discovered protein NLRC5 is demonstrated to participate in regulating cancer immune escape through enhancing MHC class I genes expression in certain tumors. Nevertheless, increasing evidence has revealed that NLRC5 is up-regulated in some other tumors and promote tumor development and progression. The purpose of this review is to describe the role of NLRC5 in tumors and discuss whether NLRC5 can be a potential target in cancer treatment.
Similar content being viewed by others
Abbreviations
- NLRC5:
-
NLR caspase recruitment domain containing protein 5
- NLRs:
-
Nucleotide-binding oligomerization domain-like receptors
- CARD:
-
Caspase activation and recruitment domain
- LRR:
-
Leucine-rich repeat
- NACHT:
-
Present in NAIP, CIITA, HET-E, and TP1proteins
- STAT1:
-
Signal transducer and activator of transcription 1
- MHC:
-
Major histocompatibility complex
- TCGA:
-
The Cancer Genome Atlas
- 5-Aza:
-
5-Azacitidine
- LUAD:
-
Lung adenocarcinoma
- LUSC:
-
Lung squamous cell carcinoma
- PRAD:
-
Prostate adenocarcinoma
- SKCM:
-
Skin cutaneous melanoma
- THCA:
-
Thyroid carcinoma
- THYM:
-
Thymoma
- UCEC:
-
Uterine corpus endometrial carcinoma
- UCS:
-
Uterine carcinosarcoma
- ESCA:
-
Esophageal carcinoma
- GBM:
-
Glioblastoma multiforme
- HNSC:
-
Head and neck squamous cell carcinoma
- KICH:
-
Kidney chromophobe
- KIRC:
-
Kidney renal clear cell carcinoma
- LAML:
-
Acute myeloid leukemia
- PAAD:
-
Pancreatic adenocarcinoma
- STAD:
-
Stomach adenocarcinoma
- TGCT:
-
Testicular germ cell tumors
- LPS:
-
Lipopolysaccharide
- HLA:
-
Human leukocyte antigen
- β2M:
-
β2-Microglobulin
- TAP:
-
Antigen processing transporter
- ER:
-
Endoplasmic reticulum
- CITA:
-
MHC class I transactivator
References
Adlung L, Kar S, Wagner MC et al (2017) Protein abundance of AKT and ERK pathway components governs cell type-specific regulation of proliferation. Mol Syst Biol 13:904
Medzhitov R, Horng T (2009) Transcriptional control of the inflammatory response. Nat Rev Immunol 9:692–703
Ruland J (2011) Return to homeostasis: downregulation of NF-κB responses. Nat Immunol 12:709–714
Velloso F J, Trombetta-Lima M, Anschau V et al (2019) NOD-like receptors: major players (and targets) in the interface between innate immunity and cancer. Biosci Rep 39(4):BSR20181709.
Moossavi M, Parsamanesh N, Bahrami A et al (2018) Role of the NLRP3 inflammasome in cancer. Mol Cancer 17:158
Tong Y, Cui J, Li Q et al (2012) Enhanced TLR-induced NF-κB signaling and type I interferon responses in NLRC5 deficient mice. Cell Res 22:822–835
Yoshihama S, Roszik J, Downs I et al (2016) NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci 113:5999–6004
Wang Q, Ding H, He Y et al (2019) NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/beta-catenin signalling pathway in clear cell renal cell carcinoma. Cancer Lett 444:9–19
Peng Y, He Y, Chen C et al (2016) NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway. Cancer Lett 376:10–21
Yao Y, Qian Y (2013) Expression regulation and function of NLRC5. Protein Cell 4:168–175
Meissner TB, Li A, Biswas A et al (2010) NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci USA 107:13794–13799
Benko S, Magalhaes JG, Philpott DJ et al (2010) NLRC5 limits the activation of inflammatory pathways. J Immunol 185:1681–1691
Kanneganti TD, Lamkanfi M, Núñez G (2007) Intracellular NOD-like receptors in host defense and disease. Immunity 27:549–559
Lamkanfi M, Kanneganti T-D (2012) Regulation of immune pathways by the NOD-like receptor NLRC5. Immunobiology 217:13–16
Meissner TB, Li A, Liu YJ et al (2012) The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity. Biochem Biophys Res Commun 418:786–791
Andreas N, Galaxia MR, Viktor S (2012) NLRC5 controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner. J Immunol 188:4940–4950
Neerincx A, Lautz K, Menning M et al (2010) A role for the human nucleotide-binding domain, leucine-rich repeat-containing family member NLRC5 in antiviral responses. J Biol Chem 285:26223–26232
Staehli F, Ludigs K, Heinz LX et al (2012) NLRC5 deficiency selectively impairs MHC class I-dependent lymphocyte killing by cytotoxic T cells. J Immunol 188:3820–3828
Cui J, Zhu L, Xia X et al (2010) NLRC5 negatively regulates the NF-κB and type I interferon signaling pathways. Cell 141:483–496
Esteller M (2006) Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 94:179–183
Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428
Creusot F, Acs G, Christman JK (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. J Biol Chem 257:2041–2048
Leonhardt H, Page AW, Weier HU et al (1992) A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell 71:865–873
Li Y, Zhang M, Zheng X (2018) High Expression of NLRC5 is associated with prognosis of gastric cancer. Open Med 13:443–449
Li X, Guo F, Liu Y et al (2015) NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients. Oncol Lett 10:1533–1540
He Y, Li M, Zhang X et al (2016) NLRC5 promotes cell proliferation via regulating the AKT/VEGF-A signaling pathway in hepatocellular carcinoma. Toxicology 359–360:47–57
Liu R, Truax AD, Chen L et al (2015) Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components. Oncotarget 6:33456–33469
Tang Z, Li C, Kang B et al (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45:W98–W102
Nonaka MI, Aizawa K, Mitani H et al (2011) Retained orthologous relationships of the MHC Class I genes during euteleost evolution. Mol Biol Evol 28:3099–3112
Braud VM, Allan DS, McMichael AJ (1999) Functions of nonclassical MHC and non-MHC-encoded class I molecules. Curr Opin Immunol 11:100–108
Johnston-Carey HK, Pomatto LC, Davies KJ (2015) The Immunoproteasome in oxidative stress, aging, and disease. Crit Rev Biochem Mol Biol 51:268–281
Blum JS, Wearsch PA, Cresswell P (2013) Pathways of antigen processing. Annu Rev Immunol 31:443–473
Peaper D, Cresswell P (2008) Regulation of MHC class I assembly and peptide binding. Annu Rev Cell Dev Biol 24:343–368
Shastri N, Cardinaud S, Schwab SR et al (2005) All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol Rev 207:31–41
Ludigs K, Seguín-Estévez Q, Lemeille S et al (2015) NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module. PLoS Genet 11:e1005088
Ting JP, Baldwin AS (1993) Regulation of MHC gene expression. Curr Opin Immunol 5:8–16
Bukur J, Jasinski S, Seliger B (2012) The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol 22:350–358
Yoshihama S, Vijayan S, Sidiq T et al (2017) NLRC5/CITA: a key player in cancer immune surveillance. Trends Cancer 3:28–38
Garrido F, Aptsiauri N, Doorduijn EM et al (2016) The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 39:44–51
Seliger B (2012) Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother 61:249–254
Angell TE, Lechner MG, Jang JK et al (2014) MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res 20:6034–6044
Siddle HV, Kreiss A, Tovar C et al (2013) Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. Proc Natl Acad Sci USA 110:5103–5108
Rodriguez GM, Bobbala D, Serrano D et al (2016) NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes. Oncoimmunology 5:e1151593
Ma HL, Zhao XF, Chen GZ et al (2016) Silencing NLRC5 inhibits extracellular matrix expression in keloid fibroblasts via inhibition of transforming growth factor-beta1/Smad signaling pathway. Biomed Pharmacother 83:1016–1021
Akhurst RJ, Hata A (2012) Targeting the TGFβ signalling pathway in disease. Nature reviews. Drug Discov 11:790–811
Fernández JG, Rodríguez DA, Valenzuela M et al (2014) Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced β-catenin/Tcf-Lef dependent transcription. Mol Cancer 13:209
Zong Z, Song Y, Xue Y et al (2019) Knockdown of LncRNA SCAMP1 suppressed malignant biological behaviours of glioma cells via modulating miR-499a-5p/LMX1A/NLRC5 pathway. J Cell Mol Med 23:5048–5062
Park WS, Oh RR, Park JY et al (1999) Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Can Res 59:4257–4260
Kumar H, Pandey S, Zou J et al (2011) NLRC5 deficiency does not influence cytokine induction by virus and bacteria infections. J Immunol 186:994–1000
Ranjan P, Singh N, Kumar A et al (2015) NLRC5 interacts with RIG-I to induce a robust antiviral response against influenza virus infection. Eur J Immunol 45:758–772
Li J, Yu L, Shen Z et al (2016) miR-34a and its novel target, NLRC5, are associated with HPV16 persistence. Infect Genet Evol 44:293–299
Periyasamy P, Thangaraj A, Bendi VS et al (2019) HIV-1 Tat-mediated microglial inflammation involves a novel miRNA-34a-NLRC5-NFκB signaling axis. Brain Behav Immun 80:227–237
Xu T, Ni MM, Huang C et al (2015) NLRC5 mediates IL-6 and IL-1β secretion in LX-2 cells and modulated by the NF-κB/Smad3 pathway. Inflammation 38:1794–1804
Zhang YZ, Yao JN, Zhang LF et al (2019) Effect of NLRC5 on activation and reversion of hepatic stellate cells by regulating the nuclear factor-κB signaling pathway. World J Gastroenterol 25:3044–3055
Robbins GR, Truax AD, Davis BK et al (2012) Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins. J Biol Chem 287:24294–24303
Ludigs K, Jandus C, Utzschneider DT et al (2016) NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. Nat Commun 7:10554
Thomas L (1982) On immunosurveillance in human cancer. Yale J Biol Med 55:329–333
Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998
Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3:999–1005
Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800
Kim JM, Chen DS (2016) Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol 27:1492–1504
Chae YK, Arya A, Iams W et al (2018) Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 6:39
Mahoney KM, Freeman GJ, McDermott DF (2015) The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 37:764–782
Contardi E, Palmisano GL, Tazzari PL et al (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538–550
Wing K, Onishi Y, Prieto-Martin P et al (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271–275
Kuenzel S, Till A, Winkler M et al (2010) The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses. J Immunol 184:1990–2000
Meng Q, Cai C, Sun T et al (2015) Reversible ubiquitination shapes NLRC5 function and modulates NF-κB activation switch. J Cell Biol 211:1025–1040
White BD, Chien AJ, Dawson DW (2012) Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology 142:219–232
Rosenbluh J, Wang X, Hahn WC (2014) Genomic insights into WNT/β-catenin signaling. Trends Pharmacol Sci 35:103–109
Yan M, Li G, An J (2017) Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions. Exp Biol Med 242:1185–1197
Lu D, Choi MY, Yu J et al (2011) Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA 108:13253–13257
Kopp F, Hermawan A, Oak PS et al (2014) Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. Mol Cancer 13:16
Qin LS, Jia PF, Zhang ZQ et al (2015) ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis. J Exp Clin Cancer Res 34:57
Li T, Su L, Zhong N et al (2013) Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells. Autophagy 9:1057–1068
He L, Lu N, Dai Q et al (2013) Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology 312:36–47
Yang L, Zhang HW, Hu R et al (2009) Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. Biochem Cell Biol 87:933–942
Wickström M, Dyberg C, Milosevic J et al (2015) Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun 6:8904
Markowski MC, Boorjian SA, Burton JP et al (2019) The microbiome and genitourinary cancer: a collaborative review. Eur Urol 75:637–646
Snijders PJ, Verhoef VM, Arbyn M et al (2013) High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 132:2223–2236
Ogino S, Chan AT, Fuchs CS et al (2011) Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60:397–411
Ogino S, Nowak JA, Hamada T et al (2019) Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Ann Rev Pathol 14:83–103
Acknowledgements
I gratefully acknowledge the Second Affiliated Hospital of Anhui Medical University.
Funding
This study was funded by the National Natural Science Foundation of China (No. 81072066).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest. Feng Tang and Yadi Xu are joint first authors. Zhao Bing and Feng Tang are joint corresponding authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tang, F., Xu, Y. & Zhao, B. NLRC5: new cancer buster?. Mol Biol Rep 47, 2265–2277 (2020). https://doi.org/10.1007/s11033-020-05253-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-020-05253-5